Molecular targeting to treat gastric cancer

doi:10.3748/wjg.v20.i38.13741

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 38

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7222)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-7) series.

Item

Count

PDF

521

WORD

342

HTML

4116

Figures (1-3)

156

Tables (1-7)

156

Sum=5291

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1035

Download

896

Sum=1931

Oct 14, 2014 (publication date) through Jul 28, 2024

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741

Table 3 Clinical trials of bevacizumab

Patients	Phase	Treatment	n	OS (m)	PFS (m)	TTP (m)	RR
Metastatic or unresectable gastric and GEJ adenocarcinoma	II	Irinotecan + cisplatin + bevacizumab	47	12.3	N/A	8.3	65%
Previously untreated metastatic gastroesophageal adenocarcinoma	II	Docetaxel + fluorouracil + bevacizumab	44	16.8	12	N/A	67%
First-line treatment for advanced gastric cancer (AVAGASTA)	III	Capecitabine + cisplatin	387	10.1	5.3	37.4	N/A
			387	12.1	6.7	46	N/A
First-line treatment for advanced gastric cancer (AVAGASTA)	III	Capecitabine + cisplatin + bevacizumab	387	12.1	6.7	46	N/A

GFJ: Gastroesophageal junction; N/A: Not available; OS: Overall survival; PFS: Progression-free-survival; RR: Response rate; TTP: Time to progression.

Citation: Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755
URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13741.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13741